source
- AI drug developer Pathos secures $237 million Series E, valuation hits $3 billionPathos announced a $237 million Series E round led by Bristol Myers Squibb, lifting its valuation to about $3 billion. The funding will support expansion beyond oncology into neurology, leveraging…
- Lycia Therapeutics raises $318 million in IPO to fund protein degrader programsLycia Therapeutics, a biotech focused on protein-degrading medicines, priced its initial public offering at about $318 million. The proceeds will be used to advance three LYTAC drug candidates, in…